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ABSTRACT 
In the U.S., breast cancer (BC) incidences among African American (AA) and CA (CA) 
women are similar, yet AA women have a significantly higher mortality rate. In addition, 
AA women often present with tumors at a younger age, with a higher tumor grade/stage 
and are more likely to be diagnosed with the highly aggressive triple-negative breast 
cancer (TNBC) subtype. Even within the TNBC subtype, AA women have a worse 
clinical outcome compared to CA. Although multiple socio-economic and lifestyle 
factors may contribute to these observed health disparities, it is essential that the 
underlying biological differences between CA and AA TNBC are identified. In this 
study, gene expression profiling was performed on archived FFPE samples, obtained 
from CA and AA women diagnosed with early stage TNBC. Initial analysis revealed a 
pattern of differential expression in the AA cohort compared to CA. Further molecular 
characterization results showed that the AA cohort segregated into 3-TNBC molecular 
subtypes; Basal-like (BL2), Immunomodulatory (IM) and Mesenchymal (M). Gene 
expression analyses resulted in 190 differentially expressed genes between the AA and 
CA cohorts. Pathway enrichment analysis demonstrated that differentially expressed 
genes were over-represented in cytoskeletal remodeling, cell adhesion, tight junctions, 
and immune response in the AA TNBC -cohort. Furthermore, genes in the Wnt/β-catenin 
pathway were over-expressed. These results were validated using RT-qPCR on an 
independent cohort of FFPE samples from AA and CA women with early stage TNBC, 
and identified Caveolin-1 (CAV1) as being significantly expressed in the AA-TNBC 
cohort. Furthermore, CAV1 was shown to be highly expressed in a cell line panel of 
TNBC, in particular, those of the mesenchymal and basal-like molecular subtype. Finally, 
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silencing of CAV1 expression by siRNA resulted in a significant decrease in proliferation 
in each of the TNBC cell lines. These observations suggest that CAV1 expression may 
contribute to the more aggressive phenotype observed in AA women diagnosed with 
TNBC.  
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Chapter 1 
INTRODUCTION 
Over 235,000 U.S. women will be diagnosed with invasive breast cancer (BC) 
each year, and it is estimated that over 40,000 women will die from the disease in 2015 
(1). Although BC incidences have increased over the past decade, BC mortality has 
shown a steady decline, most likely due to the availability of screening, earlier detection 
of breast masses, and targeted therapy. Responses to chemotherapy, hormone and 
targeted therapy, as well as overall survivorship are highly correlated with the stage at 
time of diagnosis. The earlier the stage at diagnosis, the better the overall response rate 
and 5 year survival rate (1,2). Therefore, investigations to improve the understanding of 
underlying tumor biology of early stage breast cancer and the identification of biomarkers 
to provide diagnostic and prognostic indicators are imperative. 
 Advances in understanding breast cancer through molecular subtyping 
BC is no longer thought of as a single disease. Instead, it is considered a complex 
and molecularly heterogeneous entity, varying in biology, presentation and response to 
treatment. BC classifications divide BC into categories according to different schemes, 
each based on different criteria and serving a different purpose. The major categories are 
the histopathological type, tumor grade, tumor stage and the expression patterns of 
proteins and genes. As knowledge of cancer cell biology increases, these classifications 
are revised and demonstrate a need for more effective prognostic and predictive tools 
beyond purely clinicopathological characteristics. Even before newer classification tools 
were developed, it was known that hormone receptor status, - estrogen receptor positive 
(ER+) or negative (ER-) progesterone receptor positive (PR+) or negative (PR-) - and later 
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Her2 receptor status (HER2), was correlated with significant clinical outcomes and 
therapies (2-5). ER+ tumors consistently have a better 5-year overall survival outcomes, 
as well as better response to hormonal therapies like tamoxifen and aromatase inhibitors 
(3-7). Thus, the ability to discriminate between tumors even at the “crude level” of 
receptor-type has significant treatment and prognostic value. Over a decade ago, Perou, 
Sorlie and colleagues at Stanford sought to more precisely classify breast cancer samples 
through a then unique approach termed “gene expression profiling” (8). Using a large 
scale genomic survey of breast tumors, these groups reported in a number of successive 
publications, five intrinsic subtypes that share molecular characteristics and similarities in 
tumor biology; Luminal A (Luminal A), Luminal B (Luminal B), Her2-Enriched (HER2), 
Basal-like (BLBC ), and Normal-Like (8-12). This set of publications dramatically 
changed our understanding of breast cancer and led to development of the PAM50 Breast 
Cancer Intrinsic Classifier that uses a 50-gene set to classify breast tumors into one of the 
five -recognized molecular subtypes (11). Current statistics quote that approximately 
40% of all breast cancers are molecularly classified as Luminal A; 10-20% Luminal B; 
10-20% “normal-like”; 10 % Her2 and 10-20% are BLBC (Table 1). These molecular 
subtypes have been repeatedly shown to be independent predictors of prognosis, survival, 
and response to therapy (7-13). 
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  Table 1. Molecular Subtypes of Breast Cancer:  Clinical, Pathological and     
   Molecular Characteristics. 
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The “Luminal” molecular subtypes of BC express genes and protein of keratins 
8/18, commonly associated with luminal epithelial cells. Emerging data suggests that 
Luminal A and Luminal B tumors may be distinct entities (14). Luminal A tumors 
account for 40% of all diagnosed BC and are receptor positive for estrogen (ER+) and/or 
progesterone (PR+), and negative for human epidermal growth factor receptor 2 (HER2-), 
as determined by immunohistochemistry or molecular profiling (8). Luminal A tumors 
have a low Ki67, a protein that increases in cells as they prepare to divide, indicating slow 
growth and they tend to be far less aggressive compared to other molecular subtypes. 
Therapy often includes adjuvant endocrine therapy such as an aromatase inhibitor 
(anastrozole, letrozole) or tamoxifen with or without adjuvant chemotherapy such as 
doxorubicin/cyclophosphamide followed by paclitaxel (5). As a result of their slow 
growth response to hormone therapy, and far less aggressive nature, Luminal A tumors 
have a very favorable 5 year survival prognosis.  
Luminal B tumors are characterized by ER+ and/or PR+ and HER2+ (luminal-
HER2 group) or ER+ and/or PR+, HER2−, and high Ki67 (>14%), indicating cell growth 
and division. Similar to Luminal A tumors, the typical treatment options include adjuvant 
chemotherapy followed by docetaxel. In addition, due to the Her2 protein over-
expression a typical treatment course might include of trastuzumab (Herceptin) or 
lapatinib with or without pertuzumab (Tykerb), which are often used in combination with 
the standard chemotherapy and an aromatase inhibitor such as letrozole (Femara). 
Compared to Luminal A, these tumors are diagnosed at a much younger age (>50 yrs) 
(13-15), higher tumor grade (Grade 3) (14-17). Often they fail to respond to hormone 
based therapy, probably due to the lower levels of ER-related genes relative to Luminal A 
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tumors. A study by Creighton et. al, found that Luminal B (50%) patients had a 30% 
decrease in distant metastasis-free survival compared to Luminal A (80%) patients at 
12.5 years (14). Additionally, Sorlie et al determined that Luminal A patients had an 
overall survival that was 71 months higher than in Luminal B patients (14, 10-12). These 
studies support the lower relapse-free and overall survival differences observed in the 
Luminal molecular subtypes.  
The HER2-enriched subtype (HER2+/ER−/PR−) is less common (10%), and is 
characterized by high-grade/node positive tumors. Treatment options include trastuzumab 
(Herceptin) and anthracycline-based chemotherapy. Tumors with the HER2 gene 
amplification and/or overexpression HER2 protein have a poor prognosis that includes a 
greater risk of relapse and shortened overall survival (17-20). 
BLBC accounts for 10-20% of all diagnosed breast cancers and is identified by 
the lack of clinically significant levels of protein receptors for estrogen (ER), 
progesterone (PR), or human epidermal growth factor receptor 2 (Her2) and expression 
of one or more high-molecular-weight/basal cytokeratins (CK5/6, CK14, and CK17). 
BLBC also has a high rate of metastasis that often involves brain and lung and although 
treatment options are available, overall, patients diagnosed with BLBC have a lower 
overall survival (<48 months) compared to all other molecular subtypes of breast cancer 
(7-23).  
Characteristics of TNBC 
Several studies have shown that ~70% of TNBC tumors fall into the BLBC molecular 
subtype, however, it is important to note that not all BLBC are TNBC (8-10). TNBC 
accounts for ~ 10-15% of all diagnosed breast cancers and is identified by the lack of 
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clinically significant levels of estrogen, progesterone receptors and HER2 (8-10). 
Additional characteristics of TNBC include an early age of onset (≤50), higher tumor 
grade (>3), and larger primary tumor (> 2.0 cm) (24-30). TNBC often have markers for 
basal cytokeratins, ck5/6, CK14 and CK17, as well as a myoepithelial marker P-cadherin, 
a mesenchymal marker vimentin and lower levels of E-cadherin, all suggesting 
characteristics of epithelial-mesenchymal transition (EMT), a critical event during 
metastasis (24-27). Common mutations in include genes associated with DNA-repair 
mechanisms (BRCA1) and tumor suppression (p53/RB1). TNBC also has a high rate of 
recurrence that often involves metastasis to the brain and lung (24-30). There is a lower 
detection rate of TNBC/BLBC on mammography and combined with enhanced tumor 
cell proliferation in TNBC, this may explain how TNBC can develop between yearly 
mammograms, and has been described as an “interval cancer” (25,28). Although 
treatment options are available (surgery+/- radiation; combination of platinum-based 
chemotherapy), the lack of cell surface hormone receptors often make TNBC 
unresponsive to conventional hormone or targeted therapy (24-27). Overall, patients 
diagnosed with TNBC have a much lower disease-free survival interval, lower overall 
survival, and a much worse overall prognosis and have a much higher incidence in 
minority women, African and Hispanic American women and those of African Descent  
(29,30). 
Wnt/β-catenin dependent signaling pathway (Canonical Wnt signaling) and the 
normal breast development 
The Wnt/β-catenin signaling pathway is known to play an important role in mammary 
gland development and deregulation of this pathway and associated genes have been 
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implicated in cancer initiation and progression (31). Wnt/β-catenin signaling regulates 
distinct stages of remodeling during development and the reproductive lifetime of the 
mammary gland, including involution cycles back to adult stage during pregnancy and 
lactation (31).  During the normal development of the breast, mechanisms such as 
proliferation and terminal end bud branching occur in response to Wnt/β-catenin 
signaling (31). In the absence of Wnt ligands, accumulated β-catenin is phosphorylated 
resulting in ubiquitination and degradation.  Wnt ligands bind to low-density lipoprotein 
receptor –related proteins 5/6 (LRP5/6) and Frizzled (FZD) and activate the Wnt/β-
catenin signaling pathway.  This binding/activation signals the recruitment of Disheveled 
(Dsh), which inactivates the β-catenin destruction complex.  Stabilized β-catenin 
translocates to the nucleus and the signaling effects of β-catenin are mediated through 
transcription factor 4 (TCF4) and lymphoid enhancer factor (LEF-1). The TCF4/LEF-1 
complex binds Wnt response elements, providing docking sites for β-catenin at the 
nucleus, and induces the expression of Wnt target genes that regulate the cell cycle, cell 
growth and proliferation.   
Dysregulation of Wnt signaling in Breast Cancer 
Wnt signaling is necessary for maintaining the proliferation- differentiation 
balance and dysregulation of this pathway has been shown to play a role in tumor 
development and progression in cancer and in particular,  TNBC.  For example, the 
overexpression of TCF4 in rectal cancer has been shown to confer resistant to therapy 
and was associated with a shorter overall survival (32). Caveolin-1 (CAV1), an integral 
plasma membrane protein associated with β-catenin signaling, has been shown to be 
overexpressed in BLBC and TNBC, leading to epithelial mesenchymal transition (EMT) 
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(33,34). Tenascin-C (TNC) has been shown to significantly down-regulate the Wnt 
inhibitor dickkopf, promoting Wnt signaling in glioblastoma cells (35). Finally, forkhead 
box 3A (FOXO3A) has been shown to be a pro-apoptotic transcription factor and Wnt 
signaling activator (35,36). Recently, whole genomic and transcriptome sequencing 
(RNA-seq) was performed on 14 TNBC patients, including six AA and eight CA. Unique 
homozygous deletions were seen in in two tumors (TNBC -001, TNBC -006) that 
involved α-catenin and the Wnt/β-catenin signaling pathway (adjacent CTNNA1 and 
SIL1 loci at 5q31.2)(38). Interestingly, the two tumors that exhibited this α-catenin 
homozygous deletion were both from AA breast cancer patients. Downregulation of α-
catenin, a tumor repressor that associates directly with β-catenin/cadherin complex and 
the actin skeleton, has been correlated with tumor progression and cell growth, (38). 
Recent studies have observed deregulation of the Wnt/β-catenin signaling pathway in 
TNBC and BLBC, associated with high grade, poor prognosis and metastatic disease 
(39).  However, these studies did not specifically investigate differences between CA and 
women of African descent (39,40). 
Health Disparities in Triple-negative Breast Cancer  
The Carolina Breast Cancer Study (CBCS), a population based control study which 
sought to investigate breast cancer in AA women, has improved our understanding of 
tumor molecular subtype, menopause status, tumor characteristics and survival in a large 
cohort (41,42). The CBCS statistics show that CA women actually have a higher BC 
incidence rate than AAs, followed by Hispanic, Asian/Pacific Islander, and American 
Indian/Alaska Native women (2,41-43). Additionally, AA women have a lower lifetime 
risk of developing breast cancer than CA women, yet, from 1999–2011, the CDC and 
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CBCS reported that the mortality rate for AA women (36 per 100,000) was significantly 
higher than any other group including CA (28 per 100,000) (28,30). The CBCS study 
found that young, premenopausal AA women had a high frequency of TNBC (77%) and 
lower survival (10% less) than that of CA women with TNBC. Finally, the study found 
that even after adjusting for age, race and stage TNBC was higher in AA women 
compared to CA women. As depicted in the pie chart in figure 1B, Africa American 
women and those of African descent have a larger distribution of TNBC diagnosis 
compared to women of European/Caucasian decent (29). AA women are 3-fold more 
likely to develop TNBC, often at a younger age (premenopausal) and more likely to be 
diagnosed with a higher grade tumor (>3) (28-30,41-43). Emerging evidence 
demonstrates a correlation between African ancestry and TNBC, indicating that there are 
intrinsic genes or mutations that predispose women of African descent to this more 
aggressive subtype (44). A study investigating African Ancestry and TNBC, found that 
the prevalence of TNBC diagnosis highest in Ghanaian women (82%) followed by AA 
women (26%) and CA women (16%) (45). These data suggests the possibility that 
increasing extent of African Ancestry may ‘predispose’ a woman to early onset or high-
risk breast cancer such as TNBC. The relapse-free and overall survival period is 
significantly lower in AA TNBC than in CA cohorts and AA are more likely to have a 
BRCA1 mutation (44). As illustration, a study by Mefford et al identified an inherited 
BRCA1 founder mutation, BRCA1 943ins10, in families of African ancestry (44). 
A combination of factors, including socio-economic, lifestyle, access to 
healthcare and differences in treatment protocols likely contribute to the health disparities 
that exist between AA and CA diagnosed with TNBC (44-46), but they do not fully 
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explain them. Social factors, such as poverty and restricted access to quality healthcare, 
often underestimate the ‘hidden’ factors such as lack of transportation or the inability to 
undergo therapy due to work, which can significantly minority patients (27,41,43). In 
addition to socio-economic factors, underlying differences in tumor biology and intrinsic 
factors lend support to the hypothesis that TNBC in AA is biologically different from that 
in CA. Differences in presentation or treatment (chemotherapy and/or radiation) alone do 
not account for the health disparities observe between AA and CA with TNBC (41). 
Overall, reducing a women’s lifetime exposure to estrogens, such as a higher frequency 
and duration of breast feeding and higher parity beginning at a younger age, has shown to 
be protective but only in hormone receptor positive breast cancer (2). Conversely, 
regardless of race, women with TNBC are often younger when they begin menarche 
(<12.58 yrs) and at first pregnancy (22 yrs) (46). Risk and protective factors in the 
development of TNBC have been shown to overlap between AA and CA; however there 
are some distinct differences. For example, increased parity is still considered protective 
in CA and considered a risk factor in AA women. Additionally, AA women have a 
significantly lower frequency of breastfeeding (31%) compared to CA women (58%) 
(36,45,46). This combination of risk factors, higher parity and a decreased duration of 
breast feeding in AA women, may contribute to the health disparity observed in AA with 
TNBC. A study by Stead et al. investigated TNBC and associated risk factors and found 
that the 3-fold higher prevalence of TNBC in AA women was regardless of other risk 
factors such as age or weight (29). These observations guide our research into the 
biological patterns of gene expression between AA women with TNBC and a cohort of 
CA women with this disease.  
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In this study, we performed gene expression profiling on a cohort of early stage 
(Node 0) TNBC samples from AA and CA women. Our analysis revealed a distinct 
pattern of gene expression, mostly upregulated, in the AA cohort. Using molecular 
profiling of the gene expression data, we determined that the AA TNBC cohort was of 
the BLBC molecular subtype (64%) and segregated into three of the TNBC molecular 
subtypes: Basal-like (BL2), Immunomodulatory (IM) and Mesenchymal (M). In contrast, 
the CA cohort was distributed among the six TNBC-subtypes. This suggests there are 
distinct differences between AA TNBC and CA TNBC, even in early stages of tumor 
development. Differential gene expression analysis of the expression array data resulted 
in 190 differentially expressed genes between the AA and CA cohort. Using pathway 
enrichment (GeneGo) analysis, we found that the majority of differentially expressed 
genes were over-represented in pathways such as cell adhesion, tight junctions, immune 
response and the Wnt/β-catenin pathway in the AA TNBC cohort. After validation 
experiments, we identified Caveolin-1 (CAV1) as being significantly expressed in the 
AA-TNBC cohort. In an independent cohort of TNBC Node 0, FFPE samples from AAs 
and CAs we found that the AA cohort had a significantly higher level of Cav1 protein, 
compared to the CA cohort. Using a cell line panel, we determined that CAV1, mRNA 
and protein, was higher in the TNBC cell lines than in luminal cell lines. Finally, a panel 
of TNBC cell lines was used to demonstrate that CAV1 silencing by siRNA resulted in a 
significant decrease in proliferation in each of the TNBC cell lines, while there was no 
affect observed in the luminal breast cancer cell lines. These observations suggest that 
CAV1 expression may contribute to the more aggressive phenotype observed in AA 
women diagnosed with TNBC and may be a potential biomarker and therapeutic target. 
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Chapter 2 
Figure 1. A) Age-Adjusted Breast Cancer Incidence and Death Rates in the U.S. 
by Race and Ethnicity. The BC incidence and mortality rate is grouped by race 
and ethnicity, using combined data from the National Program of Cancer 
Registries as submitted to CDC and from the Surveillance, Epidemiology and 
End Results program as submitted to the National Cancer Institute in November 
2013. Data shows that CA women had the highest incidence, followed by 
African American, Hispanic, Asian/Pacific Islander, and American 
Indian/Alaska Native women. From 1999–2011, the mortality rate for BC 
varied, depending on their race and ethnicity, however, for each year. AA 
women were significantly more likely to die of BC than any other racial group. 
(http://www.cdc.gov/cancer/breast/statistics/race.htm). B) Racial distribution of 
TNBC. As depicted in the pie chart, AA women and those of African descent 
accounted for a much larger proportion of TNBC compared to those of 
European/Caucasian descent. (Stead LA, et al, BCR 11:R18, 2009) 
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COMPARISON OF TRANSCRIPTIONAL SIGNATURES FROM U.S. AFRICAN 
AMERICAN AND CAUCASIAN WOMEN DIAGNOSED WITH EARLY STAGE 
TNBC IDENTIFIES DIFFERENTIAL EXPRESSION IN KEY ONCOGENIC 
PATHWAYS 
Abstract 
Disparities in breast cancer stage of presentation and survival rates exist in patients of 
different ethnicities. Although a women’s race alone is not considered a risk factor in 
developing BC, strong epidemiological data supports BC as the second leading cause of 
cancer death among U.S. AA women, with a 20% greater mortality rate than that of CA 
women. BC incidence rates for AA and CA women have become comparable, but AA 
women still have a higher mortality rate; AA women with BC often present with tumors 
that are of higher grade and later stage and their relapse-free and overall survival period 
is significantly lower than CA. Additionally, the more aggressive TNBC phenotype has a 
higher prevalence in AA women. Combined observations have led to a much poorer 
prognosis for AA BC patients. These differences are undoubtedly a result of a 
combination of factors; including socio-economic, lifestyle, access to health care, tumor 
characteristics and inherent factors, such as genetic composition. In order to begin to 
understand the biological differences in AA patients diagnosed with TNBC, we analyzed 
tumor and self-matched normal tissue samples from AA and CA patients from south 
Florida who were diagnosed with early stage (Node 0), TNBC . Comparisons of 
transcriptional differences between AA and CA TNBC using GeneGo pathway 
enrichment analysis, suggest expression alterations in several key pathways, including 
cytoskeletal remodeling, cell adhesion, Wnt-signaling, cell adhesion, tight junctions, and 
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immune response. This suggests that inherent gene expression differences exist between 
AA and CA TNBC samples in pathways previously-recognized as important in 
onocogenesis. Finally, the analysis revealed novel and significantly deregulated genes 
associated with the Wnt/β-catenin pathway in the AA cohort, as compared to the CA, 
suggesting this pathway may contribute to the more aggressive phenotype in AA women 
diagnosed with TNBC . 
Materials and Methods  
Tumor Material for Gene Expression Microarray Analysis 
Matched tumor and adjacent normal breast tissue FFPE samples AA and CA patients 
were obtained from the University of Miami (UM) /Sylvester Breast Tissue Bank (UM/S 
BTB) under an IRB-approved protocol, in collaboration with the Drs. Carmen Gomez, 
Merce Jorda (UM Pathology) and Mark Pegram, (UM Oncology), between 2006-2012. 
Samples were chosen based on TNBC status, lack of lymph node involvement, ethnicity, 
age, lack of exposure to adjuvant and/or chemotherapy and the availability of matched 
adjacent control. Each of the samples was evaluated using immunohistochemical staining 
to confirm ER/PR/Her2 receptor status. A total of 23 samples from AA and CA patients 
diagnosed with Lymph Node 0 TNBC, along with a pool of adjacent matched controls, 
were used in the study.  
RNA isolation and Hybridization 
Total RNA extraction was performed on tumor and matching adjacent normal FFPE 
sections, in collaboration with Almac Diagnostics, using the RecoverAll Total Nucleic 
Acid Isolation Kit for FFPE (Life Technologies). The RNA extracted was evaluated for 
concentration and purity using the Nanodrop 1000 and overall RNA integrity using the 
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Agilent Bioanalyzer. Total RNA samples that passed QC and had sufficient concentration 
were amplified with the NuGen WT-Ovation FFPE Amplification Kit v2 (NuGEN). The 
resulting cDNA product was assessed for concentration (>3.5 ug). To achieve optimum 
concentration for array processing it was necessary to amplify, pool and vacuum 
concentrate the RNA samples. The cDNA samples were fragmented and labeled with the 
NuGen Encore Biotin Module (NuGEN), then hybridized to the Almac Diagnostics 
Breast Cancer DSA (http://www.almacgroup.com/biomarker-discovery-
development/proprietary-discovery-arrays/dsa/). The BC DSA research tool is a research 
platform for the study of breast cancer that includes >60,000 biologically relevant 
transcripts, many of which are not available on traditional array, including transcripts 
expressed in normal breast tissue and unique transcripts related to cancer initiation and 
development. Almac Quality Control (QC) included the evaluation of the gene chip for 
hybridization performance and a data integrity assessment to ensure there are no 
underlying variables that may cause an unexpected pattern in the data. As these samples 
were processed from FFPE, Almac lowered the percent call from 25% to 20%. Almac 
provided raw data files, gene-to-chip annotation file and QC analysis documents to 
demonstrate that 23 of the 23 samples along with matched adjacent control data passed 
final QC and were used for downstream analysis.  
Microarray Analysis  
Gene expression analysis was conducted using GeneSpring 12.3® analytical software. 
Signal intensity value above the 20th percentile in 100% of the samples of at least 1 
experimental condition was used to filter the raw data (60,856 probe sets). 41,802 probe 
sets were normalized using the Robust MultiArray Average (RMA) technique, which 
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briefly, provides non-linear background correction on a per-chip basis, and log 
transformed to the baseline median of all samples. The normalized data set was used for 
all downstream analyses. Principal Component Analysis tool (PCA) was used to detect 
outliers and/or batch effects. After quality control assessment of array data, 23/23 
samples were retained. Prior to further analysis, low intensity signals in the  normalized 
data was filtered by expression; Step one, remove low-intensity signals of genes that are 
not expressed, Lower cut-off: 20.0/Upper cut-off: 100.0. Step two; retain entities within 
the cut-off limits. This resulted in a final total of 18,296 probes. In our first level of 
analysis, hierarchical clustering of the normalized data was examined for gene clusters 
between the AA and CA cohort. Unsupervised cluster analysis was performed using the 
hierarchical cluster algorithm, based on ethnicity and gene probes (p-value < .05, fold 
change >2.5) and Pearson’s uncentered similarity metric with centroid linkage rule. 
Differentially gene expression between the two groups were identified using the 
‘Biological Significance Workflow’ in GeneSpring 12.3®  using the Benjamani-
Hochberg multiple test correction method to reduce the false discovery rate (FDR) with a 
significance cutoff of adjusted p-value < 0.05. This method assumes independence of p-
values across genes.  
GeneGoEnrichment Pathway Analysis 
The list of differentially expressed genes with a threshold value of 1.50 (Fold Change) 
and adjusted p-value of ≤ 0.05 was imported into GeneGo for enriched pathway analysis; 
GeneGo Pathways Software (MetaCore™) (https://portal.genego.com/).  
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TNBC Type 
Using the normalized and filtered raw data, the AA and CA TNBC Node 0 cohort was 
classified by TNBC subtype using the “TNBC type: A Subtyping Tool for TNBC", 
http://cbc.mc.vanderbilt.edu/TNBC /  
Technical Validation of FOXO3A, TNC, TCF4 and CAV1 
If total RNA used in the gene expression array was depleted then the corresponding FFPE 
block was used to create three10 uM scrolls for RNA extraction using RNeasy FFPE Kit 
(Qiagen) per manufacturer’s protocol. RNA integrity and purity was measured using a 
2100 Bioanalyzer (Agilent Technologies) and concentration was determined using the 
Nanodrop ND-1000 Spectrophotometer (Nanodrop). Complementary DNA (cDNA) was 
synthesized from 1 µg of total RNA in a 20 µl reaction volume using the SuperScript III 
First-Strand Synthesis kit, per the manufacturer’s protocol (Life Technologies). 
Preamplification of cDNA was done using the TaqMan PreAmp Master Mix Kit, which 
allows use of very small of amounts of cDNA to increase the quantity of specific cDNA 
targets, without introducing amplification bias. The kit has been optimized to work 
specifically with TaqMan Gene Expression Arrays. Briefly, TaqMan GEA 
(Lifetechnologies) for FOXO3A, TNC, TCF4 and CAV1 were pooled with the PreAmp 
Master Mix (Lifetechnologies) and then added to the cDNA correlating to the samples in 
the gene expression microarray. Preamplification was setup (mixing the pooled assays 
with cDNA sample and TaqMan® PreAmp Master Mix) then run in a 96 well plate on an 
ABI 7900HT using the following program;  consisting of enzyme activation, 95°C for 10 
min; Denature, 95°C for 15 sec, Anneal/Extend 60 sec for 14 cycles.  
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Breast Cancer Cell Lines 
Breast cancer cell lines, MDAMB231 and MCF7, were used as controls in the technical 
validation. Total RNA was extracted using Trizol (phenol, guanidine isothiocyanate) 
followed by sequential precipitation with chloroform/isopropanol. The precipitated RNA 
was purified with the RNeasy Micro Kit (Qiagen), per the manufacturer’s instructions 
and RNA integrity and purity was measured using a 2100 Bioanalyzer (Agilent 
Technologies) and concentration was determined using the Nanodrop ND-1000 
Spectrophotometer (Nanodrop). Complementary DNA (cDNA) was synthesized from 1 
µg of total BC cell line RNA in a 20 µl reaction volume using the SuperScript III First-
Strand Synthesis kit, per the manufacturer’s protocol (Life Technologies).  
Reverse Transcriptase Quantitative Real-time PCR Analysis 
Relative expression levels of mRNAs were measured using the TaqMan® Gene 
Expression Assays (GEA, Life Technologies), which consist of a pair of unlabeled PCR 
primers and a TaqMan® probe with a FAM™ on the 5’ end and minor groove binder 
(MGB) and non-fluorescent quencher (NFQ) on the 3’ end. The primer probeset IDs for 
quantitative real-time PCR were as follows:  CAV1 (Hs00971716_m1), FOXO3 
(Hs04194415_s1) TCF4 (Hs00162613_m1), TNC (Hs01115665_m1) and Human ACTB 
(Β-actin) Endogenous Control. The KAPA Probe Fast qPCR Master Mix Kit designed for 
ABI Prism (KAPA Biosystems) and 100 ng of cell line control or 5 ul of diluted (1:20) 
preamplified FFPE cDNA product was used per reaction and run in triplicate. The 
following reaction protocol was used for all TaqMan RT-qPCR and analyzed on an ABI 
Prism 7900HT (Applied BioSystems):  Enzyme Activation, 95°C for 10 min; Denature, 
95°C for 15 sec, Anneal/Extend 60 sec for 40 cycles. Relative mRNA expression was 
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calculated relative to β-actin amplification using the comparative CT method, also known 
as the ΔΔCT method. First, the mean and standard deviation values of the replicates are 
calculated. Next, the CT values of both the calibrator and the samples of interest are 
normalized to Β-actin. Finally, fold-change is calculated using the ΔΔCT relative to a 
calibrator, typically the sample with the highest ΔCt. This is achieved by using the 
formula below, where Gene x could be CAV1, FOXO3A, TNC, or TCF4. Significance 
was determined using an unpaired, two-tailed t-test.  
2–ΔΔCT = [ΔΔCT Gene X = ΔCT, Target Gene – ΔCT Β-actin]- ΔΔCT Calibrator 
Results 
FFPE samples used the study were obtained from AA and CA patients with matched 
tumor and adjacent normal breast tissue from the University of Miami /Sylvester Breast 
Tissue Bank (UM/S BTB), in collaboration with the Dr. Carmen Gomez, Dr. Merce Jorda 
(UM Pathology) and Dr. Mark Pegram, (UM Oncology), between 2006-2012. As shown 
in table 2, the samples were matched for TNBC status, lymph node involvement (Node 
0), ethnicity, age and exposure to adjuvant and/or chemotherapy. In addition, each of the 
samples was evaluated using immunohistochemical staining to confirm ER/PR/Her2 
receptor status. A total of 23 samples from AA and CA patients diagnosed with Lymph 
Node 0 TNBC were used in further studies.  
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     Table 2. FFPE Tumor Sample Characteristics 
 
 
 
 
 
 
 
 
 
 
 
Neg: Negative; TNBC: Triple-Negative Breast Cancer.  
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Gene expression profiling was performed on each sample using the breast cancer 
enriched gene expression array Affymetrix Platform, Breast Cancer DSA Research Tool 
(BC DSA). The BC DSA research tool has a 3′ focus providing an optimized platform for 
the analysis of samples from FFPE, laser capture microdissection and fine needle 
aspirates. This research tool includes > 60,000 biologically relevant transcripts, many of 
which are not available on traditional array, including transcripts expressed in normal 
breast tissue and unique transcripts related to cancer initiation and development.  
A total of 60,856 gene/probes were checked for quality control of the gene chip and gene 
probes. Gene expression analysis was conducted using GeneSpring 12.3® analytical 
software. The combined samples were hybridized on different dates and geographical 
locations; therefore our first step was to determine if there was any batch effect, which 
could cause non-biological variations in the gene expression data. A PCA analysis was 
performed, based on batch date, and it was determined that there were no non-
biologically relevant variations (Fig. 2). 
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Figure 2. PCA Analysis:  No Batch Effect Observed. Total RNA was isolated from 
FFPE samples, amplified and hybridized to the Almac Breast Cancer DSA™ 
(Affymetrix Platform), which includes over 60,000 probes for normal breast and BC. 
Gene Expression analysis was conducted using GeneSpring 12.3 analytical software, 
briefly; Robust Multi-Array Average (RMA) for background correction was performed 
to normalize baseline to median and Log2 transform the raw data. Principal component 
analysis (PCA) was performed to determine if Batch Effect occurred. Although the 
samples were processed in multiple batches, the PCA data demonstrates that a ‘Batch 
Effect’ did not occur and 23/23 samples were retained. 
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The data was normalized and filtered by expression to remove any unreliable expression 
values, including probe sets representing genes that are not expressed in any of the 
samples or if they had values too high or too low to be considered biologically relevant. 
This pre-filtering step created a revised list of 14,802 gene/probes for further analysis. 
Using matched adjacent normal tissue as controls, unsupervised hierarchical cluster 
analysis was performed (p-value <.05, fold change >2.0) and Pearson’s un-centered 
similarity metric with centroid linkage rule. Results are depicted in a heatmap (Fig. 3), 
and revealed a pattern of differential expression in the AA Tumor cohort compared to 
CA. All subsequent experiments will be comparing the AA and CA TNBC, Node 0, 
cohort.  
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Figure 3. Heatmap of TNBC-Node 0, AA and CA Cohort. 
Unsupervised hierarchical clustering was performed on each 
tumor cohort using the gene list derived from the pre-filtered 
probe list. Using a pool of matched adjacent normal tissue as 
controls, unsupervised hierarchical cluster analysis was 
performed (p-value <.05, fold change >2.0) using the Pearson’s 
un-centered similarity metric with centroid linkage rule. Results 
revealed a majority of down-regulated genes (shown in red) 
found in the AA Tumor cohort compared to CA.  
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To identify the genes that were differentially expressed between the AA TNBC and CA 
TNBC cohorts the filtered list of 14,802 gene/probes was used. Using the ‘Biological 
Significance Workflow’ in GeneSpring 12.3®; the gene list was analyzed by an unpaired 
t- test by Benjamani-Hochberg Multiple Test Correction Method to reduce False 
Discovery Rates (FDR) with a significance cutoff of adjusted p-value < 0.05. After 
filtering for duplicate genes a total of 190 differentially expressed genes (DEGs), 
including 173 up-regulated and 17 down-regulated, were identified in the AA TNBC 
Node 0 cohort (Table 3). The list of DEG was then imported into GeneGo Pathways 
Software (MetaCore™) to identify biological processes or enriched pathways that 
consistently display differential expression between the AA and CA cohort.  
The AA TNBC gene expression profile was enriched for pathways in cytoskeletal 
remodeling, cell adhesion, Wnt, cell adhesion, tight junctions, and immune response (Fig. 
4). Additionally, we observed significantly upregulated genes associated with the Wnt/β-
catenin pathway in the top six pathways; CAV1, FOXO3A, TNC and TCF4 (Fig. 5). 
Based on the results from the gene enrichment pathways, AA compared to CA, and 
current literature we chose to investigate the following genes and there role in the more 
aggressive TNBC; CAV1, FOXO3A, TNC and TCF4. 
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Table 3. List of Differentially Expressed Genes, AA vs CA.
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Figure 4. Functionally Enriched Pathways in TNBC -Node 0, AA vs. 
CA Cohorts. The DEG list from table 2, was imported into Metacore 
GeneGo to identify functionally enriched pathways. The AA Cohort 
was enriched for pathways in cytoskeletal remodeling, cell adhesion, 
Wnt, cell adhesion, tight junctions, and immune response. 
Additionally, we observed significantly upregulated genes associated 
with the Wnt/β-catenin pathway in the top 10 pathways. 
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Figure 5. Representative GeneGo Enrichment for of the Wnt-β-catenin 
Pathway, AA TNBC compared to CA TNBC. The red thermometer 
indicates that the associated gene is significantly upregulated in the 
AA cohort compared to the CA cohort. Significant genes of interest 
was enriched for the Wnt/β-catenin pathway are circled in red.  
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Large scale genomic surveys of breast tumors using microarray-based technologies reveal 
at least five predominating molecular subtypes. The predominating subtypes (Basal-like, 
Luminal B, Her2-enriched, Luminal B, Luminal A and Normal Breast-like) share 
molecular characteristics and similarities underlying tumor biology and have contributed 
to improved prognostication and clinical decision-making (8-13). In addition, there are at 
least six TNBC subtypes including 2 basal-like (BL1 and BL2), an immunomodulatory 
(IM), a mesenchymal (M), a mesenchymal stem–like (MSL), and a luminal androgen 
receptor (LAR) subtype (48-49). It is also known that AA TNBC patients are enriched in 
the basal and immunomodulatory subtypes. In order to further characterize the molecular 
subtype of the AA and CA patients used in the Node 0 TNBC cohort, two accepted 
subtype predictor algorithms - the PAM50-defined subtype predictor and the “TNBC 
type: A Subtyping Tool for TNBC” were applied to each cohort (9, 48-49).  
The PAM50-Defined Subtype Predictor algorithm revealed that the majority of the AA-
cohort classified into Basal-Like (BLBC ) Molecular Subtype (64%), which includes the 
TNBC -phenotype and that the CA Cohort also included the BLBC -subtype, however, at 
a lower percentage than AA (46%). Additionally, the CA Cohort contained larger 
percentages of the HER2 (23%) and Luminal B (23%) subtypes (Fig. 6A). Further 
characterization using the TNBC type Tool, found that the CA-TNBC Cohort have a 
common distributed among the six of the TNBC molecular subtypes using the TNBC 
type Tool (48,49). In contrast, the AA Cohort was comprised primarily of 3-TNBC 
molecular subtypes; 14% Basal-like (BL2), 43% Immunomodulatory (IM) and 43% 
Mesenchymal (M) (Fig. 6B).  
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A 
B 
Figure 6. Molecular Subtyping of the TNBC -Node 0, AA and CA 
Cohorts. A) Using the PAM50-Defined Subtype Predictor algorithm, the 
cohorts were classified into one of the predominating molecular 
subtype(s). The AA Cohort (64%) and CA Cohort (46%) comprised of 
mainly the Basal-Like Molecular Subtype that includes the TN-phenotype. 
Additionally, the CA Cohort included 23% of the HER2 and Luminal B 
subtypes. B) TNBC Subtyping of TNBC -Node 0, AA and CA Cohorts. 
TNBC subtype was performed using a web-based prediction tool; TNBC 
type: A Subtyping Tool for TNBC, http://cbc.mc.vanderbilt.edu/TNBC/. 
The AA Cohort comprised primarily of 3-TNBC molecular subtypes; 14% 
Basal-like (BL2), 43% Immunomodulatory (IM) and 43% Mesenchymal 
(M). The CA TNBC Cohort was distributed among all six of the TNBC 
molecular subtypes. 
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Microarray results showed significantly upregulated genes associated with the Wnt/β-
catenin pathway in the top six pathways; CAV1, FOXO3A, TNC and TCF4 (Fig. 4). 
Gene expression microarrays provide a snapshot of the transcriptional activity in a 
sample and within a cohort, however, there is sample variability, technical and user 
variations associated with these types of experiments. In addition, use of RNA isolated 
from archived FFPE samples is difficult process and requires careful QC at each process. 
Our experimental design was created with these difficulties in mind; however, it was still 
necessary to validate our findings. Using Life Technologies Taqman GEA created for 
each of the candidate genes we performed RT-qPCR using the remaining RNA; from 7-
AA Tumor, 7-AA controls from adjacent normal tissue, 8-CA Tumor and 3-CA Controls. 
Significance was determined using an unpaired, two-tailed t-test. CAV1 expression was 
significantly higher (p = 1.22 x 10-05) in the AA TNBC cohort compared to the TNBC CA 
cohort (Fig. 7). 
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Figure 7. Technical Validation of Candidate Genes. RNA from the Affymetrix 
BC DSA was pre-amplified using the TaqMan PreAmp Master Mix Kit prior to 
cDNA synthesis. If total RNA used in the gene expression array was depleted 
then the corresponding FFPE block was used extract RNA. TaqMan Gene 
Expression Assays for FOXO3A, TNC, TCF4 and CAV1 were used to measure 
relative expression levels of mRNA, calculated relative to β-actin amplification 
using the comparative CT method. Significance was determined using an 
unpaired, two-tailed t-test. CAV1 expression was significantly higher (p-Value 
1.22-05) in the AA TNBC cohort compared to the CA cohort. 
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Conclusion 
Although multiple factors may contribute to the observed health disparities in TNBC, it is 
essential that we identify the molecular characteristics and any underlying biological 
differences between CA and AA TNBC. In collaboration with the University of Miami 
/Sylvester Breast Tissue Bank (UM/S BTB), we obtained FFPE samples from AA and 
CA patients women diagnosed with early stage, Node 0 TNBC. Gene expression 
profiling was performed on each sample, matched tumor and adjacent normal breast 
tissue, using Affymetrix Breast Cancer DSA Research Tool (BC DSA). Unsupervised 
hierarchical cluster analysis of the gene expression data revealed a pattern of differential 
expression in the AA Tumor cohort compared to CA, with mostly upregulated genes in 
the AA. Differential gene expression analysis identified 190 genes, 173 up-regulated and 
17 down-regulated, in the AA cohort pathway enrichment analysis identified that the AA 
TNBC gene expression profile was enriched for pathways in cytoskeletal remodeling, cell 
adhesion, Wnt-β-catenin, cell adhesion, tight junctions, and immune response (Fig. 4). 
Interestingly, we observed significantly upregulated genes associated with the Wnt/β-
catenin pathway in the top six pathways; CAV1, FOXO3A, TNC and TCF4 (Fig. 5). 
These results were validated using the Taqman Gene Expression Assay for each of the 
candidate genes with remaining RNA from each cohort. We determined that CAV1 
expression was significantly higher (p-Value = 1.22 x 10-05) in the AA TNBC cohort 
compared to the TNBC CA cohort (Fig. 7).  
We also found that the basal-like breast cancer subtype was the predominate molecular 
subtype in the AA (64%) cohort, and that the AA Cohort was comprised primarily of 3-
TNBC molecular subtypes; 14% Basal-like (BL2), 43% Immunomodulatory (IM) and 
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43% Mesenchymal (M) (Fig. 6B). These data suggest that the even at the earliest stage of 
TNBC, there are significant differences among AA and CA tumors and suggest that in 
this cohort CAV1 expression may contribute to the more aggressive phenotype observed 
in AA women diagnosed with early stage TNBC. 
Caveolin-1 (CAV1) gene is located on chromosome 7 (locus 7q31.1), near the 
fragile site, FRA7G locus. This gene includes three exons (30, 165 and 342 bp) and two 
introns (1.5 and 32 kb). CAV1 is a scaffolding protein and the main component of the 
caveolae that make up the plasma membrane and involved cell signaling and molecular 
transport, cell adhesion, intracellular trafficking of lipid and cholesterol (50). Although 
CAV1 is ubiquitously expressed, it is highest in adipocytes, endothelial, epithelial and 
myoepithelial cells and less in luminal cells (51,52). CAV1 in cancer appears to be 
tumor/stage and even subtype specific and although there have been published reports of 
CAV1 as a tumor suppressor in cancer (colon, ovary, lung), data is increasing suggesting 
an oncogenic role for CAV1 (53-55). Increased CAV1 levels induced EMT and cell 
survival and showed that serum levels could predict risk of relapse in pancreatic cancer 
(55-58). Similarly in hepatocellular carcinoma (HCC), CAV1 expression induced 
Epithelial–mesenchymal transition (EMT) through the Wnt/β-/β-catenin-TCF/LEF 
pathway, and was a potential biomarker for worse prognosis (59). In prostate cancer, 
CAV1 has been shown to be a biomarker to identify patients at high risk of recurrence 
(60). High CAV1 expression in tumor and loss in stromal cells has been shown to be 
predictive of poor survival in BC (61). CAV1 and CAV2 have been shown to associate 
with BLBC and TNBC (61-62) and shown to correlate with increased cell proliferation, 
migration and invasion in the same subtype (63). CAV1 gene amplification in metaplastic 
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and BLBC and associated with lower overall survival and is preferentially expressed in 
basal-like BC and cell lines (51). However, the role of CAV1 in health disparities of 
TNBC has not yet been addressed.  
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CHAPTER 3 
CAV1 IS EXPRESSED IN AN INDEPENDENT COHORT OF AA-TNBC SAMPLES 
AND MESENCHYMAL/BASAL-LIKE TNBC CELL LINES 
Abstract 
In order to validate the CAV1 results (Fig. 7), an independent cohort of TNBC Node 0 
FFPE samples from patients matched for race/ethnicity, age, prior treatment, pathological 
stage and confirmed TNBC status was used to construct a tissue microarray (TMA). In 
addition, a panel of triple-negative and ER+ breast cancer cell lines were used to 
characterize endogenous CAV1 expression in vitro. Results demonstrated that CAV1 
expression was differentially expressed among molecular subtypes of TNBC and ER+ 
BC. The TNBC -Group 1, consisting of mesenchymal and basal-like TNBC cell lines, 
expressed high levels of CAV1 mRNA and endogenous protein. TNBC -Group 2, 
consisting of epithelial-like TNBC cell lines, expressed lower levels of CAV1 mRNA 
and protein. Data suggests that CAV1 expression may be a candidate biomarker of TNBC 
with mesenchymal characteristics in AA women.  
Materials and Methods 
Cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA) and were maintained in RPMI-1640 (MDA-MB-231, MDA-MB-157, T47D, 
MCF7),or RPMI-1640 with a supplement of 0.01 mg/ml insulin (HCC70, HCC1806) 
medium. Cells were maintained with 10% fetal bovine serum (FBS) and 1x Penicillin-
Streptomycin, in constant humidity at 37°C in 5% CO2. All media and supplements were 
obtained from Life Technologies (Carlsbad, CA).  
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SDS-PAGE and Western blotting  
Whole cell protein lysates were prepared using a RIPA lysis buffer kit that contained a 
protease inhibitor cocktail in DMSO and phosphatase inhibitors (odium sodium 
orthovandate, phenylmethylsulfonyl fluoride) per the manufacturer instructions (Santa 
Cruz). Protein samples from wild-type BC cell lines were collected when cell lines were 
~75% confluent to minimize variability in expression due to cell density and the protein 
concentration was determined using Pierce BCA Protein Assay Kit (Life Technologies). 
Approximately 30 μg of Cav1/lane was separated using 4-12% Bis-Tris precast gels in 
MES buffer in the NuPage electrophoresis system (Invitrogen). Protein was transferred 
onto Invitrolon PDF membranes using the iBlot Dry Blotting System (Life Technologies) 
for 6 min, per the manufacturer instructions. Each membrane was incubated in nonfat dry 
milk (Walmart) blocking solution consisting of 5% nonfat dry in tris-buffered saline with 
0.1% Tween (TBST; Sigma). Western blotting was performed using rabbit monoclonal 
antibody to Cav1 and (ab52938) and loading control, alpha-tubulin, a rabbit polyclonal 
antibody (ab52866) was purchased from Abcam. The Horseradish peroxidase-conjugated 
secondary antibody was purchased from GE Healthcare (anti-rabbit; Pittsburgh, PA) and 
each were used at a dilution of 1:12,000. All antibodies (primary and secondary) were 
incubated for 1 hr, at room temperature on a rocking platform. SuperSignal West Femto 
Maximum Sensitivity Substrate was used to develop the western blots followed by 
chemiluminescence detection high sensitivity film for autoradiography (USA Scientific).  
Independent Cohort of TNBC Node 0 FFPE Samples 
An independent cohort of Node 0 TNBC FFPE tissue samples from AA (13) and CA (10) 
patients were obtained from three vendors;  Asterand Bioscience, Advanced Tissue 
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Services (ATS) and National Disease Research Interchange (NDRI). Samples were 
chosen based on similar characteristics from our original samples in chapter 2; TNBC 
status, Stage 0-Stage IIB (AJCC Staging), < 60 years of age and no prior adjuvant or 
chemotherapy. The FFPE blocks were used to construct a multi-ethnic TNBC Tissue 
MicroArray (TMA) and for independent validation of CAV1 mRNA expression using 
RT-qPCR.  
Total RNA Isolation from FFPE Samples and cDNA Synthesis 
Total RNA isolation from the independent cohort of TNBC FFPE samples was extracted 
using the RNeasy FFPE Kit (Qiagen) per manufacturer’s protocol. Total RNA from the 
TNBC Cell Line Panel was extracted, as described in chapter2, following the Qiagen 
RNeasy Kit protocol. RNA integrity and purity was measured using a 2100 Bioanalyzer 
(Agilent Technologies) and concentration was determined using the Nanodrop ND-1000 
Spectrophotometer (Nanodrop). Complementary DNA (cDNA) was synthesized from 1 
µg of total RNA in a 20 µl reaction volume using the SuperScript III First-Strand 
Synthesis kit, per the manufacturer’s protocol (Life Technologies).  
Quantitative Real-time PCR Analysis 
Relative expression levels of mRNAs were measured using the TaqMan® GEA, as 
described in chapter 2. The primer probeset ids for RT-qPCR were as follows:  CAV1 
(Hs00971716_m1) and Human ACTB (Β-actin) Endogenous Control. The KAPA Probe 
Fast qPCR Master Mix Kit designed for ABI Prism (KAPA Biosystems) was used for all 
PCR amplifications and analyzed on an ABI Prism 7900HT. The 20 ul reaction was 
prepared with 5ul of cDNA, 10 ul of 2X Kapa Master Mix, 1 ul 20x TaqMan® GEA and 
4 ul H2O, and run in triplicate. The following reaction protocol was used for all TaqMan 
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RT-qPCR and analyzed on an ABI Prism 7900HT (Applied BioSystems):  Enzyme 
Activation, 95°C for 10 min; Denature, 95°C for 15 sec, Anneal/Extend 60 sec for 40 
cycles. Expression levels of mRNA were calculated using the comparative CT method, as 
described in chapter 2. Significance was determined using an unpaired, two-tailed t-test.  
TMA Construction staining and scoring 
The TMA was constructed in the Macromolecular Analysis & Processing Center 
(MAPC) at TGen. Each FFPE block used in the construction of the TMA block is 
represented as double-punched 0.6 mm diameter core biopsy on the array along with 
positive (uterus) and negative (testis) internal controls. The slides made from the TMA 
block were subjected to heat induced epitope retrieval using a proprietary citrate based 
retrieval solution for 20 minutes. Endogenous peroxidase was blocked and all slides were 
incubated for 30 minutes with a rabbit monoclonal antibody to Cav1 (ab52938) at a 
dilution of 1:1000 obtained from Millipore (Abcam). The sections were visualized using 
the Bond Polymer Refine Detection kit (Leica) using diaminobenzidine chromogen as 
substrate and then counterstained with hematoxylin. Once dry the TMAs were 
coverslipped with permamount and reviewed by the MAPC resident pathologist. Each 
individual core was scored for Cav1 location (stromal cell or nuclear) along with 
matching stain intensity (0-3). In addition, an HScore was derived from a semi-
quantitative assessment of both staining intensity (scale 0–3) and the percentage of 
positive cells (0–100%), which, when multiplied, generated a score ranging from 0 to 
300. Statistical analysis was performed using a student’s t-test.   
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Results 
To characterize the expression levels of CAV1, nine breast cancer cell lines were used. 
The nine cell lines and their characteristics including ER, PR, and HER2 expression 
status are shown in Table 4. The TNBC cell lines consisted of three ER-negative 
mesenchymal BC cell lines (BT549, MDAMB-231, MDAMB-157), three ER-negative, 
epithelial-like BC cell lines (BT20, HCC70, MDAMB468), a basal-like ER-negative 
(HCC1806) and two ER-positive, luminal A BC cell lines (MCF7, T47D). CAV1 mRNA 
expression was determined using RT-qPCR. The TNBC -Group 1 of high CAV1 mRNA 
expression included the three ER-negative mesenchymal BC cell lines (BT549, 
MDAMB-231, MDAMB-157) and the basal-like ER-negative (HCC1806). The TNBC -
Group 2, included the three ER-negative, epithelial-like BC cell lines (BT20, HCC70, 
MDAMB468). MCF7, the ER-positive, luminal A BC cell line had expression levels 
similar to TNBC -Group 1 while T47D, consistently lacked CAV1 mRNA expression 
(Fig 8A). Similar to mRNA expression, TNBC -Group 1 had a higher level of 
endogenous Cav1 protein expression compared to TNBC -Group 2. MCF7 had Cav1 
protein expression comparable to the TNBC -Group 1 and T47D, again lacked evidence 
of Cav1 expression (Fig 8B).    
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  Table 4. Clinicopathological Characteristics of the Breast Cancer Cell Line Panel. 
 
   
 
 
All data on the cell lines was obtained from ATCC and 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730521/ 
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Figure 8. Cell Line Panel of CAV1 Expression. A) cDNA was prepared from total 
RNA from each of the cell lines and the TaqMan Gene Expression Assay for CAV1 
and β-actin was performed.  Relative expression levels of CAV1 mRNA, calculated 
relative to β-actin amplification was determined using the comparative CT method. 
B) Cav1 Endogenous Protein Expression. Western blot analysis, using cell lysates 
from each of the cell lines, revealed differential expression of endogenous Cav1.  
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Using archived FFPE samples from 13-AA and 10-CA women diagnosed with TNBC, an 
independent cohort of TNBC Node 0 TMA was constructed. Patient clinical annotation is 
listed in Table 5. Immunohistochemistry was performed to determine the location of 
Cav1 (nucleus, cytoplasm or membrane) along with stain intensity (0-3) in the AA and 
CA TNBC cohort. In addition, an H-Score was derived from a semi-quantitative 
assessment of both staining intensity (scale 0–3) and the percentage of positive cells (0–
100%), which, when multiplied, generated a score ranging from 0 to 300. Cav1 
Expression is higher in the AA TNBC Cohort. The Cav1 stain intensity showed no 
difference in Cav1 location between the AA and CA cohort of TNBC (Fig 9A-B). The 
AA cohort of TNBC had a significantly higher HScore for Cav1 compared to the CA 
cohort (Fig 9C). 
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ID number Ethnicity Gender AJCC Stage Diagnosis Sample Source
SM08­4907 AA Female I IDC ATS
SM08­5190 AA Female I IDC ATS
312966A1 AA Female IA MC Asterand
312996A2 AA Female IA IFDC Asterand
313004A3 AA Female IA IFDC Asterand
S11­1838 AA Female IA IDC ATS
SM08­1816 AA Female IA IDC ATS
313005A3 AA Female IIA IFDC Asterand
343307A1 AA Female IIA IFDC Asterand
SM08­4047 AA Female IIA IDC ATS
SM10­1587 AA Female IIA IDC ATS
SM10­1637 AA Female IIA IDC ATS
SM11­2677 AA Female IIA IDC ATS
ND03627 CA Female IA IDC NRDI
ND03628 CA Female IA IDC NRDI
313450B2 CA Female IA IFDC Asterand
313497A1 CA Female IA IFDC Asterand
ND03625 CA Female IIA IDC NRDI
ND03626 CA Female IIA IDC NRDI
ND03629 CA Female IIA IDC NRDI
313500A3 CA Female IIA IFDC Asterand
313514A2 CA Female IIA IFDC Asterand
343294A2 CA Female IIA MC Asterand
Table 5. TNBC Node 0, Independent Cohort Clinical 
Annotation.  
ATS, Advance Tissue Services; NDRI, National Disease Research 
Interchange; IDC, Invasive Ductal Carcinoma; IFDC, Infiltrating 
Ductal Carcinoma; MC, Metastatic Carcinoma 
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Fig 9. Cav1 Expression is higher in an Independent Cohort of the AA TNBC. A) 
Immunohistochemistry of high (right) and low (left) in TNBC tissue sections stained with 
the anti-Cav1 antibody. B) Cav1 stain intensity (0-3).  There is no difference between 
location of Cav1 between the AA and CA cohort of TNBC. C)  The percent tumor and 
stain intensity were used to calculate an Hscore. Results show that the AA cohort of 
TNBC had a significantly higher HScore for Cav1 compared to the CA cohort.  
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Conclusion 
A cell line panel of triple-negative and ER+ breast cancer cell lines were used to 
characterize endogenous CAV1 expression in vitro. Results demonstrated that CAV1 was 
differentially expressed among molecular subtypes of TNBC and ER+ BC. The TNBC -
Group 1, consisting of mesenchymal and basal-like TNBC cell lines, expressed high 
levels of CAV1 mRNA and endogenous protein. TNBC -Group 2, consisting of 
epithelial-like TNBC cell lines, expressed lower levels of CAV1 mRNA and protein (Fig 
8).  
In order to validate the CAV1 results (Fig. 7), an independent cohort of TNBC Node 0 
FFPE samples from patients with matched for race/ethnicity, age, prior treatment, 
pathological stage and confirmed TNBC status was used to construct a tissue microarray 
(TMA). In addition, using the same archived FFPE samples from 13-AA and 10-CA 
women diagnosed with TNBC, tissue microarray (TMA) was constructed. Patient clinical 
annotation is listed in Table 5. Immunohistochemistry was performed to determine the 
location of Cav1 (nucleus, cytoplasm or membrane) along with stain intensity (0-3) in the 
AA and CA TNBC cohort. In addition, an H-Score was derived from a semi-quantitative 
assessment of both staining intensity (scale 0–3) and the percentage of positive cells (0–
100%), which, when multiplied, generated a score ranging from 0 to 300. Cav1 
Expression is higher in the AA TNBC Cohort. The Cav1 stain intensity showed no 
difference in Cav1 location between the AA and CA cohort of TNBC (Fig 9A-B). The 
AA cohort of TNBC had a significantly higher HScore for Cav1 compared to the CA 
cohort (Fig 9C). 
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Data suggests that CAV1 expression may be a candidate biomarker of TNBC with 
mesenchymal characteristics in AA women.  
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CHAPTER 4 
SILENCING OF CAVEOLIN-1 INHIBITS CELL PROLIFERATION IN  
TNBC CELL LINES 
Abstract 
CAV1 has been implicated as an oncogene in BC, a biomarker of aggressive disease and 
been shown to promote proliferation and invasion. In this study, small interfering RNA 
(siRNA) technology was used to inhibit the expression of CAV1 in TNBC cell lines 
followed by suppression of CAV1 to determine the role of CAV1 on proliferation. The 
TNBC , ER-negative mesenchymal BC cell lines, MDAMB-231, MDAMB-157, and 
basal-like ER-negative line, HCC1806, that expressed high levels of endogenous Cav1 
along with the ER-negative, epithelial-like BC cell lines HCC70, were used to assess the 
functional role of Cav1 in TNBC . Additionally, the two ER-positive, luminal A BC cell 
lines, MCF7, and T47D were used. TNBC cell lines, mesenchymal and epithelial-like, 
exhibited a decrease in cell proliferation compared to the luminal A BC cell lines, MCF7, 
T47D. 
Materials and Methods  
Cell lines used were obtained from the ATCC (Manassas, VA) and were maintained in 
RPMI-1640 (MDA-MB-231, MDA-MB-157, T47D, MCF7), or RPMI-1640 with a 
supplement of 0.01 mg/ml insulin (HCC70, HCC1806) medium. Cells were maintained 
with 10% fetal bovine serum (FBS) and 1x Penicillin-Streptomycin, in constant humidity 
at 37°C in 5% CO2. All media and supplements were obtained from Life Technologies 
(Carlsbad, CA).  
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Transfection of siRNA 
Three Silencer® Select pre-designed and validated siRNAs to CAV1 (id: s2446, s2447, 
s2448) were purchased from Life Technologies. Optimal transfection conditions were 
determined using Lipofectamine® RNAiMAX Transfection Reagent, GAPDH positive 
and scrambled negative control #1 siRNAs (AM4605) and KDalert GAPDH Assay Kit 
(Life Technologies). Optimal siRNA transfection parameters; 0.60 ul Lipofectamine® 
RNAiMAX Transfection Reagent, 30 nM siRNA, and the reverse transfection method, all 
prepared in Opti-MEM® I Reduced Serum Medium (Life Technologies) were used to 
determine which siRNA had the best reduction in target mRNA levels. Each of the three 
CAV1 siRNAs were used with the MDAMB-157 cell line and measured by RT-qPCR as 
described above. Although each of the CAV1-siRNAs reduced mRNA and protein levels, 
CAV1 s2446 had the highest level of transfection efficiency and was used for all 
subsequent transfection of siRNA. For downstream siRNA isolations, 5 x 104 cells per 
well were used in reverse transfection method and seeded into clear, 96-well plates 
triplicate with a total volume of 200 ul. Opaque walled, 96-well plates seeded at 5 x 104 
cells per well were used for downstream proliferation assays. Protein validation plates 
were seeded in duplicate at 5 x 105 cells per well into 6-well plates with a final volume of 
2000 ul.  
SDS-PAGE and Western blotting  
Whole cell protein lysates were prepared as described in Chapter 2. Protein was isolated 
at; 24, 48, 72, and 120 –hrs post siRNA and were performed using 2-wells of a 6-well 
plate. The concentration of protein was low, as determined using the Pierce BCA Protein 
Assay Kit (Life Technologies) and was concentrated approximately 30-fold with Amicon 
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Ultra Centrifugal Filter Devices (10,000 nominal molecular weight limit; Millipore). 
Approximately 10 μg Cav1/lane was separated using 4-12% Bis-Tris precast gels in MES 
buffer in the NuPage electrophoresis system (Invitrogen). Protein was transferred onto 
Invitrolon PDF membranes using the iBlot Dry Blotting System (Life Technologies) for 6 
min, per the manufacturer’s instructions. Western blot analysis was performed, described 
in Chapter 3, using a rabbit monoclonal antibody to Cav1 and (ab52938)  and alpha-
tubulin.   
Cell Proliferation 
Cell proliferation rates were determined by measuring ATP levels with the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega), which uses a proprietary thermostable 
luciferase reaction. 100 ul of supernatant was removed from the 96 well plate and 100 ul 
of room temperature CellTiter-Glo buffer was added, gently mixed and incubated at room 
temperature for 2 hrs. ATP, which is indicative of metabolically active cells, was 
measured at 24, 48, 72, 96 and 120 hrs post siRNA transfection, using the Cytation 
Multi-Mode Reader and collected in the Gen5 Data Analysis Software (BioTek). Each 
cell line has a different doubling-time; therefore, we choose to run the assay to 120 hrs, 
instead of the typical 96 hrs, in order to capture any changes in cell proliferation based on 
the loss of CAV1. GraphPad Prism Software (GraphPad Software Inc.) was used to 
obtain the proliferation rate, using nonlinear regression and the exponential growth 
equation (doubling time; (k is ln(2)/K )). Next, the proliferation rate of the CAV1 siRNA 
transfected cell lines were compared to the proliferation rate of the scrambled negative 
control, using an unpaired t-test.  
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RNA Isolation from TNBC Cell Lines and cDNA Synthesis 
For samples collected post-siRNA transfection the following procedure was used to 
isolate RNA and synthesize cDNA. Each of the six breast cancer cell lines was seeded 
into 96-well plates at 5 x 104 cells/well. RNA was isolated at 72, 96 and 120 hrs post 
siRNA using the Cells-to-cDNA II Kit (Life Technologies). Each plate was washed 2x in 
cold PBS, followed by addition of 100 ul of the Cell Lysis Buffer, heating the samples to 
75°C for 15 min, to simultaneously lyses the cells and inactivate RNases. DNase 
digestion is then performed by adding 2 ul of DNase and incubating for 15 min at 37oC, 
to remove any genomic DNA followed by an inactivation step of 75oC for 5 min. The 
crude RNA lysate (10 ul) was immediately used in complementary DNA (cDNA) 
synthesis in a 40 µl reaction volume using the SuperScript III First-Strand Synthesis kit, 
per the manufacturer’s protocol (Life Technologies) followed by RNase H incubation to 
remove the RNA strand of an RNA-DNA hybrid.  
Reverse-Transcriptase Quantitative Real-time PCR Analysis 
Relative expression levels of mRNAs were measured using the TaqMan® GEA, as 
described in chapter 2, and Probe Fast qPCR Master Mix Kit designed for ABI Prism 
(KAPA Biosystems) was used for all PCR amplifications and analyzed on an ABI Prism 
7900HT. The primer probeset ids for quantitative real-time PCR were as follows:  CAV1 
(Hs00971716_m1) and Human ACTB (Β-actin) Endogenous Control. The following 
reaction protocol was used for all TaqMan RT-qPCR and analyzed on an ABI Prism 
7900HT (Applied BioSystems):  Enzyme Activation, 95°C for 10 min; Denature, 95°C 
for 15 sec, Anneal/Extend 60 sec for 40 cycles. Relative mRNA expression was using the 
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comparative CT method as described in chapter 2. Significance was determined using an 
unpaired, two-tailed t-test. The CAV1 percent knockdown (%KD) for each cell line was 
determined using the results of the comparative CT method and the calculation below. 
% KD Calculation 
− [Δ][Δ] CT = [Δ]  Control - [Δ] CT siRNA-CAV1 
− (1- [Δ][Δ] CT)*100  = % KD of CAV1 
Results 
CAV1 siRNA-directed gene knockdown was performed using the reverse transfection 
method. The cell lines were seeded in equal number for CAV1-siRNA or Scrambled-
negative control and cell proliferation was determined at 24, 48, 72, 96 and 120 hrs post-
siRNA using the Cell TiterGlo assay. An overview of the experimental design is shown 
in Figure 10. The TaqMan Gene Expression Array was used to determine the efficiency 
of transcript knockdown. The TNBC , ER-negative mesenchymal BC cell line, MDAMB-
157, the ER-negative, epithelial-like BC cell lines, and the MCF7 and T47D showed 
transcripts that were successfully knocked down (> 94%) (Fig. 11). The TNBC ER-
negative mesenchymal lines, MDAMB-231, and the basal-like ER-negative line, 
HCC1806 achieved  >60% knockdown (Fig. 11). Cav1 protein expression to monitor 
siRNA efficiency is depicted at 120 hrs post siRNA transfection (Fig. 12). Finally, TNBC 
cell lines, mesenchymal and epithelial-like, exhibited a decrease in cell proliferation 
compared to siRNA-scrambled control and the luminal A breast cancer cell lines, MCF7, 
T47D (Fig. 13).  
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Figure 10. Overview of Experimental Design. The reverse transfection method was 
used with the Silencer® Select pre-designed and validated siRNAs to CAV1 and 
Lipofectamine® RNAiMAX Transfection Reagent. A panel of breast cancer cell 
lines were used to perform the a proliferation assay and validation of CAV1 
silencing for each breast cancer cell line was determined by western blot and RT-
qPCR technologies.  
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Figure 11. Validation of CAV1 Silencing of mRNA Expression. TaqMan Gene 
Expression Assays for CAV1 and β-actin was performed using cDNA prepared from 
total RNA isolated each of the cell lines.  The comparative CT method was used to 
calculate the relative expression levels of CAV1 mRNA (solid blue bar).  The CAV1 
percent knockdown (% KD) (striped blue bar) for each cell line was determined by 
using the results of the comparative CT method. 
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Figure 12. Validation of Cav1 Silencing of Protein 
Expression. Western blot analysis between 72, 96 and 120-
hrs post transfection.  Cell lysates from each of the cell lines 
were probed using Cav1and α-tubulin antibodies. Results 
are representative of three separate experiments and 
demonstrate a decrease in endogenous Cav1 expression in 
response to CAV1 siRNA treatment, when compared to 
scrambled and negative control.  
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Figure 13. CAV1 Silencing Inhibits Cell Proliferation in TNBC Cell Lines. 
Cell proliferation rates were determined by measuring ATP levels with the 
CellTiter-Glo luminescent cell viability assay, at 24, 48, 72, 96 and 120 hrs 
post siRNA transfection. The proliferation rate was determined using the 
nonlinear regression and the exponential growth equation in GraphPad 
Prism.  First, scrambled negative-control and CAV1-siRNA results were 
adjusted for background by using the results of the negative control and 
depicted in the graphs above. Then the adjusted proliferation rate 
(doubling time; (k is ln(2)/K )) of siRNA treated and scrambled negative 
control were  compared using unpaired t- test, ** p<.0001 (table 6).  
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Table 6. CAV1-siRNA Significantly Decreased TNBC Cell Line Proliferation. 
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Conclusion 
CAV1 has been implicated as an oncogene in BC, as a biomarker of aggressive disease 
and has been shown to promote proliferation and invasion. In this study, we used siRNA 
technology to silence the expression of CAV1 mRNA in a panel of four-TNBC and two-
luminal cell lines. We used RT-qPCR and western blot technology to confirm CAV1 
mRNA and protein silencing throughout the experiment. The majority of the TNBC cell 
lines and both luminal cell lines displayed >90% knockdown efficiency (Fig, 11). Two of 
the highest endogenous expressers of CAV1, the TNBC mesenchymal line, MDAMB-
231, and the basal-like HCC1806 achieved > 60% knockdown (Fig. 11). As depicted in 
figure 12, the Cav1 protein decreased in the CAV1-siRNA treated and increased in the 
corresponding scrambled negative control for each of the four TNBC cell lines. We found 
that the TNBC cell lines that expressed both high and moderate levels of endogenous 
CAV1 exhibited a decrease in cell proliferation, compared to scrambled negative controls 
while the luminal cell lines showed no effect (Fig 13, Table 6). 
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
This study presents a potential biological contributor to the observed health 
disparities between AA and CA women diagnosed with TNBC. First, a distinct pattern of 
gene expression was identified by unsupervised hierarchical clustering of gene expression 
array data derived from a cohort of TNBC from AA and CA women diagnosed with 
lymph node 0 diseases. The CA cohort segregated into all six of the TNBC subtypes 
while the AA cohort was comprised of mainly the Basal-like 2 (14%), 
Immunomodulatory (43%) and Mesenchymal (43%) TNBC subtypes. Next, comparative 
marker selection revealed 190 differentially expressed genes between the AA cohort and 
CA cohort; most of which were downregulated in the AA cohort. These observations 
demonstrate that even at the earliest stage of this disease, underlying differences in tumor 
biology exist between these cohorts.  
Aberrant Wnt signaling has been shown to play a role in tumor development and 
progression in cancer and in particular, TNBC. Recent studies have observed 
deregulation of the Wnt/β-catenin signaling pathway in TNBC and BLBC, associated 
with high grade, poor prognosis and metastatic disease (47). However, these studies did 
not specifically investigate differences between CA and women of African descent (46-
47). The data generated in this study, revealed that genes that were differentially 
expressed between the AA and CA cohort were over-represented in pathways associated 
with cytoskeletal remodeling, cell adhesion, tight junctions, and Wnt-β-catenin. 
Additionally, candidate genes investigated in this study (FOX03A, TNC, TCF4, CAV1) 
were shown to be over-expressed in the top 10-enrichment pathways and preferentially 
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involved in the Wnt-β-catenin pathway. Although technical validation of the original 
Almac samples identified CAV1 as being significantly expressed in the AA-TNBC 
cohort, the other candidate genes may deserve further investigation. It is possible that 
increasing the size of each cohort may reveal a significant correlation between any or all 
of the candidate genes. For instance, FOX03a has been shown to bind to the cav-1 
promoter in idiopathic pulmonary fibrosis, which leads to an increase in endogenous 
levels of cav-1 mRNA and protein expression (64).  
Technical validation of CAV1 overexpression in AA women with early stage 
TNBC was performed using an independent cohort of FFPE samples. First, IHC results 
confirmed Cav1 expression in both cohorts, although preferentially localized in the 
cytoplasm and plasma membrane. These results were expected considering the role of 
CAV1 at the plasma membrane. Although CAV1 is necessary in the normal development 
of the breast, more so in the myoepithelial cells/less in luminal cells, it was of great 
interest that Cav1 protein and mRNA expression was significantly higher in the AA 
cohort compared to the CA  (51,53). Using cell line models of TNBC and RNAi 
technology we demonstrated that loss of endogenous CAV1 expression decreased the 
overall rate of cell proliferation in the TNBC cell lines, but had no effect on the luminal 
breast cancer cell lines, MCF7 and T47D. This would suggest a functional role of CAV1 
in TNBC, even at the earliest stage of disease.  
CAV1 has been termed a ‘Molecular Hub’, due to its role at the plasma 
membrane where it is involved in numerous signaling pathways such as Ras/Mek/Erk and 
Rock/Src (50-52). CAV1 has been shown to be a tumor suppressor in the colon, ovary, 
lung and in ER+ breast cancer (54-56). A study by Wiechen et al, found that CAV1 
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expression was lower in ovarian tumor samples and when over expressed in an ovarian 
cancer cell line it resulted in suppression of cell survival, suggesting a tumor suppressor 
role in ovarian cancer (55). There is controversy regarding the role of CAV1 in cancer, 
however these differences in seem to be dependent on the tumor grade, location and even 
the subtype of cancer. For example, within the human lung cancer types, small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC), CAV1 seems to have very 
different roles; acing as a tumor suppressor in in SCLC and an oncogene in NSCLC (56). 
Additionally, CAV1 expression has been shown to be higher in metastatic versus primary 
cancers (53,57). Strong evidence seems to support CAV1 as an oncogene in bladder, 
thyroid, prostate, renal, and pancreatic cancer (50, 51, 58, 59). CAV1 has been shown to 
be an oncogene and possible biomarker of aggressive disease and predictive of relapse in 
prostate cancer (57,59,60). Of particular interest to this study, CAV1 overexpression has 
been shown to play a role in proliferation, migration and invasion and to be increased in 
BLBC/TNBC (51,53,61,62). Increased CAV1 expression in tumors has been associated 
with EMT, metastasis and resistance to therapy (50,51, 53,58). Location of CAV1 in BC 
has also been investigated and data suggest that high expression in tumor and low 
expression in stroma may be associated with poor prognosis (63).  
TNBC, regardless of race, lack the common hormone receptors/targets required 
for conventional hormone or targeted therapy and have a lower relapse free and lower 
overall survival period compared to other subtypes of breast cancer. Although race is not 
considered a risk factor in the development of breast cancer, health disparities do exist. 
There is a high prevalence of TNBC in African American women and women with 
African Ancestry and this cohort has been shown to have an overall worse clinical 
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outcome compared to Caucasian women with the same disease. CAV1 may promote 
tumor progression, metastasis, and invasion and is highly expressed in ER- breast cancer 
cell lines, and the overexpression in our African American TNBC cohort may confer the 
unfavorable outcomes in AA women with TNBC. The combined study results suggest 
that CAV1 over -expression may be a biological contributor to the observed health 
disparity between AA women and CA diagnosed with early stage TNBC. 
Future Directions 
The observations from this study are striking considering a small initial sample 
size; additional studies involving TNBC from both AA and CA women would need to 
include an increased sample size. Additionally, there needs to be further investigations 
into all the differentially expressed genes between these cohorts. These studies should 
include exploring the interaction between the genes from the initial DEG list, which may 
lead to novel TNBC-specific pathways.  
CAV1 overexpression has been shown to play a role not only in proliferation but 
also in migration and invasion and is associated with EMT, metastasis and resistance to 
therapy (50,51,53, 58,61,62). In this study, only the rate of proliferation was examined 
and additional studies will be necessary to further elucidate the functional role of CAV1 
expression in TNBC. These studies would include the use of siRNA technologies to 
evaluate potential effects on migration, invasion, apoptosis, and EMT. Additionally, 
using patient derived xenograft models (PDX) of TNBC, investigations involving the 
levels of tumor CAV1 expression and chemosensitiviy to currently available treatment 
regimens could determine if CAV1 is a potential indicator of response to therapy.  
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It may be possible to exploit the high expression of CAV1 in tumors, based on the role of 
Cav1 at the plasma membrane by using nanoparticle albumin-bound (Nab) drug(s) to 
treat women with early stage TNBC. Nab technology uses the albumin receptor and 
CAV1 pathway to achieve targeted drug therapy and accumulation (65). A recent 
investigation into nab-paclitaxel (Nab-P) and combination therapy with carboplatin has 
shown some very promising results. They found that higher Cav1 expression in tumor-
associated stroma was significantly associated with improved relapse-free survival and 
overall survival in advanced NSCLC patients (65). Finally, in a resent clinical trial 
(NCT00777673) using weekly Nab-P combination therapy (carboplatin followed by 
doxorubicin plus cyclophosphamide with concurrent bevacizumab) it was found that the 
majority of the TNBC patients achieved pathological complete response (66).  
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